Literature DB >> 20028821

Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.

Christopher L Peatey1, Katherine T Andrews, Nina Eickel, Timothy MacDonald, Alice S Butterworth, Katharine R Trenholme, Donald L Gardiner, James S McCarthy, Tina S Skinner-Adams.   

Abstract

The stage-specific antimalarial activities of a panel of antiretroviral protease inhibitors (PIs), including two nonpeptidic PIs (tipranavir and darunavir), were tested in vitro against Plasmodium falciparum. While darunavir demonstrated limited antimalarial activity (effective concentration [EC(50)], >50 microM), tipranavir was active at clinically relevant concentrations (EC(50), 12 to 21 microM). Saquinavir, lopinavir, and tipranavir preferentially inhibited the growth of mature asexual-stage parasites (24 h postinvasion). While all of the PIs tested inhibited gametocytogenesis, tipranavir was the only one to exhibit gametocytocidal activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028821      PMCID: PMC2825985          DOI: 10.1128/AAC.01512-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Antimalarial activity of sera from subjects taking HIV protease inhibitors.

Authors:  Andrew M Redmond; Tina Skinner-Adams; Katherine T Andrews; Donald L Gardiner; John Ray; Mark Kelly; James S McCarthy
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

2.  A green fluorescent protein-based assay for determining gametocyte production in Plasmodium falciparum.

Authors:  Matthew W A Dixon; Christopher L Peatey; Donald L Gardiner; Katharine R Trenholme
Journal:  Mol Biochem Parasitol       Date:  2008-11-05       Impact factor: 1.759

3.  Effect of antimalarial drugs on Plasmodium falciparum gametocytes.

Authors:  Christopher L Peatey; Tina S Skinner-Adams; Matthew W A Dixon; James S McCarthy; Donald L Gardiner; Katharine R Trenholme
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

4.  Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Authors:  B A Larder; K Hertogs; S Bloor; C H van den Eynde; W DeCian; Y Wang; W W Freimuth; G Tarpley
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

Review 5.  Tipranavir: a novel nonpeptidic protease inhibitor of HIV.

Authors:  Jennifer R King; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  HIV and malaria co-infection: interactions and consequences of chemotherapy.

Authors:  T S Skinner-Adams; J S McCarthy; D L Gardiner; K T Andrews
Journal:  Trends Parasitol       Date:  2008-05-02

7.  From malaria control to eradication: The WHO perspective.

Authors:  Kamini Mendis; Aafje Rietveld; Marian Warsame; Andrea Bosman; Brian Greenwood; Walther H Wernsdorfer
Journal:  Trop Med Int Health       Date:  2009-05-26       Impact factor: 2.622

8.  Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria.

Authors:  Richard O Otieno; Collins Ouma; John M Ong'echa; Christopher C Keller; Tom Were; Eliud N Waindi; Marian G Michaels; Richard D Day; John M Vulule; Douglas J Perkins
Journal:  AIDS       Date:  2006-01-09       Impact factor: 4.177

Review 9.  New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.

Authors:  Amelia Hughes; Tristan Barber; Mark Nelson
Journal:  J Infect       Date:  2008-06-16       Impact factor: 6.072

10.  Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assay.

Authors:  Sébastien Briolant; Philippe Parola; Thierry Fusaï; Marilyn Madamet-Torrentino; Eric Baret; Joël Mosnier; Jean P Delmont; Daniel Parzy; Philippe Minodier; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2007-04-16       Impact factor: 2.979

View more
  18 in total

1.  Brief Report: Antimalarial Benefit of HIV Antiretroviral Therapy in Areas of Low to Moderate Malaria Transmission Intensity.

Authors:  Scott Greenhalgh; Charlotte V Hobbs; Sunil Parikh
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

2.  Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.

Authors:  Youjia Li; Li Qin; Nanzheng Peng; Guangjie Liu; Siting Zhao; Zhengxiang He; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

Review 3.  Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination.

Authors:  Rashad Abdul-Ghani; John C Beier
Journal:  Parasitol Res       Date:  2014-09-04       Impact factor: 2.289

4.  HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.

Authors:  Kimberly A Porter; Stephen R Cole; Joseph J Eron; Yu Zheng; Michael D Hughes; Shahin Lockman; Charles Poole; Tina S Skinner-Adams; Mina Hosseinipour; Doug Shaffer; Ronald D'Amico; Frederick K Sawe; Abraham Siika; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; James S McCarthy; Steven R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  The effect of antiretrovirals on Plasmodium falciparum liver stages.

Authors:  Charlotte V Hobbs; Patricia De La Vega; Scott R Penzak; Jillian Van Vliet; Urszula Krzych; Photini Sinnis; William Borkowsky; Patrick E Duffy
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

6.  In vitro activity of antiretroviral drugs against Plasmodium falciparum.

Authors:  Christian Nsanzabana; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

7.  HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.

Authors:  Christopher Schwake; Michael R Baldwin; William Bachovchin; Shreeya Hegde; James Schiemer; Carolyn Okure; Andrew E Levin; Edouard Vannier; Toshihiko Hanada; Athar H Chishti
Journal:  Biochem Biophys Res Commun       Date:  2019-07-13       Impact factor: 3.575

8.  HIV treatments have malaria gametocyte killing and transmission blocking activity.

Authors:  Charlotte V Hobbs; Takeshi Q Tanaka; Olga Muratova; Jillian Van Vliet; William Borkowsky; Kim C Williamson; Patrick E Duffy
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

9.  Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies.

Authors:  Gloria Ikilezi; Jane Achan; Abel Kakuru; Theodore Ruel; Edwin Charlebois; Tamara D Clark; Philip J Rosenthal; Diane Havlir; Moses R Kamya; Grant Dorsey
Journal:  Am J Trop Med Hyg       Date:  2013-01-28       Impact factor: 2.345

10.  The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

Authors:  Tina S Skinner-Adams; Alice S Butterworth; Kimberly A Porter; Ronald D'Amico; Fred Sawe; Doug Shaffer; Abraham Siika; Mina C Hosseinipour; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; Shahin Lockman; Joseph J Eron; Steven R Meshnick; James S McCarthy
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.